AUSTIN, Texas and RARITAN, N.J., May 24 /PRNewswire-FirstCall/ -- Luminex Corporation , a manufacturer of proprietary microsphere array technology for multiplexed bioassays, and Zeus Scientific, a leading manufacturer of EIA and IFA autoimmune, infectious, parasitic and bacterial assays, signed an agreement to provide, through Zeus' U.S. marketing partner, reagent kits and instrumentation for routine autoimmune disease testing to one of the United States' largest clinical reference laboratories.
Zeus' U.S. marketing partner confirmed they had executed an agreement with a major U.S. clinical reference laboratory, whose name was not disclosed, and that the laboratory had completed validation of the System for ANA/ENA testing. The agreement between Zeus and Luminex includes placement of Luminex instruments at the laboratory's multiple sites across the U.S. This agreement is the first of its kind with one of the nation's large reference labs for the Zeus-Luminex product and represents a major milestone for the two companies.
Luminex's xMAP(R) technology is used by their multiple partners to analyze up to 100 markers per single sample. Zeus markets the Luminex xMAP technology under the AtheNA brand. The AtheNA Multi-Lyte(R) ANA Test System takes advantage of xMAP technology's multiplexing ability to test 10 different autoimmune disease markers simultaneously.
"In autoimmune disease, doctors often order tests for multiple candidate diseases at once. The Zeus kits enable customers to significantly improve testing efficiency and throughput by combining these tests into a single assay," noted Scott Tourville, President, Zeus Scientific. "We see significant potential in multiplexing and look forward to further adoption of the autoimmune tests and other offerings using the Luminex technology."
Luminex CEO, Patrick J. Balthrop, noted, "This agreement represents a significant step toward large scale commercial use of Luminex-based instruments and reagents for immunoassay testing. As stated in our strategic conference call in December, diagnostic immunoassay testing is one of six key market segments Luminex is focusing on for the future. Autoimmune diseases are complex, and our multiplexing xMAP technology is especially effective at testing complex diseases such as these. We are pleased that one of our strategic partners, Zeus, has successfully provided multiplexed immunoassay testing to one of the world's leading clinical reference laboratories. This represents an example of our business model success -- licensing Luminex's xMAP technology to partners who provide development and distribution in their areas of expertise."
Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company's xMAP system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is already in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP can be obtained on the Internet at http://www.luminexcorp.com/ .
For more information, contact:
Harriss T. Currie
Vice President, Finance
Chief Financial Officer
Zeus Scientific, Inc.
Luminex Corporation; Zeus Scientific, Inc.
CONTACT: Harriss T. Currie, Vice President, Finance, Chief FinancialOfficer of Luminex Corporation, +1-512-219-8020, or email@example.com ;or Zeus Scientific, Inc., +1-908-526-3744, or fax, +1-908-526-2058